Natural killer T cells and rheumatoid arthritis: friend or foe?

Arthritis Res Ther. 2005;7(2):88-9. doi: 10.1186/ar1714. Epub 2005 Feb 14.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Adjuvants, Immunologic / therapeutic use
  • Animals
  • Arthritis, Experimental / drug therapy
  • Arthritis, Experimental / etiology
  • Arthritis, Experimental / immunology
  • Arthritis, Experimental / therapy
  • Arthritis, Rheumatoid / immunology*
  • Arthritis, Rheumatoid / therapy
  • Autoimmune Diseases / immunology*
  • Autoimmune Diseases / therapy
  • Cytokines / physiology
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Galactosylceramides / pharmacology
  • Galactosylceramides / therapeutic use
  • Glycolipids / pharmacology
  • Glycolipids / therapeutic use
  • Humans
  • Immunotherapy, Adoptive
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / immunology*
  • Killer Cells, Natural / transplantation
  • Lymphocyte Activation / drug effects
  • Mice
  • Mice, Inbred C57BL
  • Receptors, Antigen, T-Cell, alpha-beta / analysis
  • Receptors, Neurokinin-1 / analysis
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocyte Subsets / transplantation
  • Transforming Growth Factor beta / physiology
  • Transforming Growth Factor beta1

Substances

  • Adjuvants, Immunologic
  • Cytokines
  • Galactosylceramides
  • Glycolipids
  • Receptors, Antigen, T-Cell, alpha-beta
  • Receptors, Neurokinin-1
  • TGFB1 protein, human
  • Tgfb1 protein, mouse
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1
  • alpha-galactosylceramide
  • tetracosanoic acid 1-galactopyranosyloxy-3,4-dihydroxydec-2-yl amide